Articles published by Merck & Co., Inc.

...

Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

August 25, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

August 24, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

August 18, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older

August 03, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Announces Second-Quarter 2023 Financial Results

August 01, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer

July 28, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

July 27, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma

July 26, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK MRNA

Merck Announces Fourth-Quarter 2023 Dividend

July 25, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Receives Positive European Union CHMP Opinion for Gefapixant

July 21, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)

July 21, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

July 19, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck to Hold Second-Quarter 2023 Sales and Earnings Conference Call on Aug. 1

June 29, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

June 20, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Completes Acquisition of Prometheus Biosciences, Inc.

June 16, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

June 16, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

U.S. District Court for the District of New Jersey Rules in Favor of Merck in Patent Infringement Lawsuit Related to BRIDION® (sugammadex)

June 13, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist, in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) at EASL 2023

June 12, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer

June 08, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

U.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients

June 06, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

June 06, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC

June 03, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma

June 03, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

June 01, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

May 25, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Announces Third-Quarter 2023 Dividend

May 23, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck to Present Extensive New Research Demonstrating Significant Progress in the Treatment of Certain Earlier Stage Cancers and in Advancing Broad Oncology Pipeline at 2023 ASCO Annual Meeting

May 15, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck to Participate in Bank of America Securities 2023 Healthcare Conference

May 03, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Update on FDA Advisory Committee Vote on LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone in First-Line Metastatic Castration-Resistant Prostate Cancer

April 28, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

Merck Announces First-Quarter 2023 Financial Results

April 27, 2023

From Merck & Co., Inc.

Via Business Wire

Tickers MRK

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.